Tate M Johnson1, Kyle A Register2, Cynthia M Schmidt3, James R O'Dell1, Ted R Mikuls1, Kaleb Michaud4, Bryant R England1. 1. University of Nebraska Medical Center and Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha. 2. University of Utah, Salt Lake City. 3. McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha. 4. University of Nebraska Medical Center, Omaha, and FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas.
Abstract
OBJECTIVE: There are conflicting reports on the validity of the multi-biomarker disease activity (MBDA) score for assessing rheumatoid arthritis (RA) disease activity. Our aim was to perform a systematic review of the MBDA and a meta-analysis of the correlation between the MBDA and other RA disease activity measures. METHODS: A systematic review was performed by searching Medline, Embase, Scopus, Google Scholar, and the Cochrane Library from inception to March 7, 2017. Study details, MBDA performance, and study quality were assessed by independent reviewers. Correlations of the MBDA with composite RA disease activity measures were pooled using random-effects meta-analyses. RESULTS: A total of 22 studies were identified in the systematic review, of which 8 (n = 3,242 assays) reported correlations of the MBDA with RA disease activity measures. Pooling results from these 8 studies in the meta-analysis, the MBDA demonstrated modest correlations with the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP; r = 0.41, 95% confidence interval [95% CI] 0.36-0.46) and the Disease Activity Score using the erythrocyte sedimentation rate (DAS28-ESR; r = 0.48, 95% CI 0.38-0.58), with weaker correlations observed with the Simplified Disease Activity Index (SDAI; r = 0.35, 95% CI 0.26-0.43), Clinical Disease Activity Index (CDAI; r = 0.26, 95% CI 0.19-0.33), and Routine Assessment of Patient Index Data 3 (RAPID3; r = 0.23, 95% CI 0.19-0.27). Correlations between change in MBDA and change in disease activity measures ranged from r = 0.53 for the DAS28-ESR to r = 0.26 for the CDAI. CONCLUSION: The MBDA demonstrates moderate convergent validity with the DAS28-CRP and the DAS28-ESR but weaker correlations with the SDAI, CDAI, and RAPID3. While it appears to complement existing RA disease activity measures, further assessment of the performance characteristics of the MBDA is warranted.
OBJECTIVE: There are conflicting reports on the validity of the multi-biomarker disease activity (MBDA) score for assessing rheumatoid arthritis (RA) disease activity. Our aim was to perform a systematic review of the MBDA and a meta-analysis of the correlation between the MBDA and other RA disease activity measures. METHODS: A systematic review was performed by searching Medline, Embase, Scopus, Google Scholar, and the Cochrane Library from inception to March 7, 2017. Study details, MBDA performance, and study quality were assessed by independent reviewers. Correlations of the MBDA with composite RA disease activity measures were pooled using random-effects meta-analyses. RESULTS: A total of 22 studies were identified in the systematic review, of which 8 (n = 3,242 assays) reported correlations of the MBDA with RA disease activity measures. Pooling results from these 8 studies in the meta-analysis, the MBDA demonstrated modest correlations with the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP; r = 0.41, 95% confidence interval [95% CI] 0.36-0.46) and the Disease Activity Score using the erythrocyte sedimentation rate (DAS28-ESR; r = 0.48, 95% CI 0.38-0.58), with weaker correlations observed with the Simplified Disease Activity Index (SDAI; r = 0.35, 95% CI 0.26-0.43), Clinical Disease Activity Index (CDAI; r = 0.26, 95% CI 0.19-0.33), and Routine Assessment of Patient Index Data 3 (RAPID3; r = 0.23, 95% CI 0.19-0.27). Correlations between change in MBDA and change in disease activity measures ranged from r = 0.53 for the DAS28-ESR to r = 0.26 for the CDAI. CONCLUSION: The MBDA demonstrates moderate convergent validity with the DAS28-CRP and the DAS28-ESR but weaker correlations with the SDAI, CDAI, and RAPID3. While it appears to complement existing RA disease activity measures, further assessment of the performance characteristics of the MBDA is warranted.
Authors: Jeffrey R Curtis; Annette H van der Helm-van Mil; Rachel Knevel; Tom W Huizinga; Douglas J Haney; Yijing Shen; Saroja Ramanujan; Guy Cavet; Michael Centola; Lyndal K Hesterberg; David Chernoff; Kerri Ford; Nancy A Shadick; Max Hamburger; Roy Fleischmann; Edward Keystone; Michael E Weinblatt Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Michael Centola; Guy Cavet; Yijing Shen; Saroja Ramanujan; Nicholas Knowlton; Kathryn A Swan; Mary Turner; Chris Sutton; Dustin R Smith; Douglas J Haney; David Chernoff; Lyndal K Hesterberg; John P Carulli; Peter C Taylor; Nancy A Shadick; Michael E Weinblatt; Jeffrey R Curtis Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240
Authors: Annette H M van der Helm-van Mil; Rachel Knevel; Guy Cavet; Tom W J Huizinga; Douglas J Haney Journal: Rheumatology (Oxford) Date: 2013-01-03 Impact factor: 7.580
Authors: Karen Hambardzumyan; Rebecca Bolce; Saedis Saevarsdottir; Scott E Cruickshank; Eric H Sasso; David Chernoff; Kristina Forslind; Ingemar F Petersson; Pierre Geborek; Ronald F van Vollenhoven Journal: Ann Rheum Dis Date: 2014-05-08 Impact factor: 19.103
Authors: Nadia M T Roodenrijs; Melinda Kedves; Attila Hamar; György Nagy; Jacob M van Laar; Désirée van der Heijde; Paco M J Welsing Journal: RMD Open Date: 2021-01
Authors: Jeffrey R Curtis; Michael E Weinblatt; Nancy A Shadick; Cecilie H Brahe; Mikkel Østergaard; Merete Lund Hetland; Saedis Saevarsdottir; Megan Horton; Brent Mabey; Darl D Flake; Rotem Ben-Shachar; Eric H Sasso; T W Huizinga Journal: Arthritis Res Ther Date: 2021-01-04 Impact factor: 5.156
Authors: György Nagy; Nadia M T Roodenrijs; Désirée van der Heijde; Jacob M van Laar; Paco M J Welsing; Melinda Kedves; Attila Hamar; Marlies C van der Goes; Alison Kent; Margot Bakkers; Polina Pchelnikova; Etienne Blaas; Ladislav Senolt; Zoltan Szekanecz; Ernest H Choy; Maxime Dougados; Johannes Wg Jacobs; Rinie Geenen; Johannes Wj Bijlsma; Angela Zink; Daniel Aletaha; Leonard Schoneveld; Piet van Riel; Sophie Dumas; Yeliz Prior; Elena Nikiphorou; Gianfranco Ferraccioli; Georg Schett; Kimme L Hyrich; Ulf Mueller-Ladner; Maya H Buch; Iain B McInnes Journal: Ann Rheum Dis Date: 2021-08-18 Impact factor: 19.103
Authors: Brent A Luedders; Tate M Johnson; Harlan Sayles; Geoffrey M Thiele; Ted R Mikuls; James R O'Dell; Bryant R England Journal: Semin Arthritis Rheum Date: 2020-06-17 Impact factor: 5.532
Authors: Josef S Smolen; Roberto Caporali; Thomas Doerner; Bruno Fautrel; Fabrizio Benedetti; Burkhard Pieper; Minjun Jang Journal: RMD Open Date: 2021-06
Authors: Ying-Qian Mo; Ze-Hong Yang; Jun-Wei Wang; Qian-Hua Li; Xin-Yun Du; T W Huizinga; X M E Matthijssen; Guang-Zi Shi; Jun Shen; Lie Dai Journal: Arthritis Res Ther Date: 2019-12-11 Impact factor: 5.156